Bluebird Bio Inc (BLUE) 159.39 $BLUE The Zacks Analyst

New Post Public Reply Private Reply Replies (0) Message Board

Jul 28, 2015 at 1:52 PM

Bluebird Bio Inc (BLUE) 159.39 $BLUE

The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis
BLUE: 159.39 (-0.10), BIIB: 315.64 (+6.21), LGND: 106.47 (+3.92), REGN: 557.98 (+17.95), EXEL: 5.55 (+0.11)

Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Jul 27, 9:58AM CDT
Biogen's (BIIB) shares lost more than 20% on issues regarding its oral MS treatment as well as disappointing pipeline updates.
BLUE: 159.39 (-0.10), BIIB: 315.64 (+6.21), LGND: 106.47 (+3.92), AMGN: 172.81 (+7.27), REGN: 557.98 (+17.95), EXEL: 5.55 (+0.11), CELG: 135.62 (+3.06)

Biogen's Possible Takeout Targets and Other Key Questions After Blow-Up
at The Street - Mon Jul 27, 9:30AM CDT
After cutting its revenue growth forecast, will Biogen buy itself back into investors' good graces?
BLUE: 159.39 (-0.10), BIIB: 315.64 (+6.21), NBIX: 51.98 (+2.64), ISIS: 54.57 (+0.89), SRPT: 32.35 (+0.35), RCPT: 227.75 (+0.66)

What's in bluebird bio's Pipeline That Has Investors So Excited?
Brian Feroldi, The Motley Fool - Motley Fool - Sun Jul 19, 9:02AM CDT
Clinical-stage biotechnology company bluebird bio has been a stellar investment for early investors, with the stock up more than 500% since coming public in 2013. However, since bluebird has yet to bring a product to market, investors have been...
BLUE: 159.39 (-0.10)

Market's Not in the Mood to Move
at The Street - Wed Jul 15, 3:24PM CDT
Attention turns to earnings and away from Greece, Fed.
SGYP: 8.17 (-0.02), BLUE: 159.39 (-0.10), AMBA: 122.02 (+2.57), NFLX: 107.19 (+0.76), EYES: 14.19 (-0.17), AMZN: 524.40 (-7.01), ZIOP: 12.53 (+0.50), LNKD: 225.82 (+5.16), FB: 94.74 (+0.57), RCPT: 227.75 (+0.66), LBIO: 8.97 (+0.18), INTC: 28.87 (+0.52), ONTY: 3.46 (+0.11), CELG: 135.62 (+3.06)

Market Shrugs Off Yellen
at The Street - Wed Jul 15, 12:25PM CDT
She didn't say anything to spook the market, but didn't say anything bullish either.
SGYP: 8.17 (-0.02), BLUE: 159.39 (-0.10), AMBA: 122.02 (+2.57), NFLX: 107.19 (+0.76), EYES: 14.19 (-0.17), AMZN: 524.40 (-7.01), ZIOP: 12.53 (+0.50), LNKD: 225.82 (+5.16), FB: 94.74 (+0.57), RCPT: 227.75 (+0.66), LBIO: 8.97 (+0.18), INTC: 28.87 (+0.52), ONTY: 3.46 (+0.11), CELG: 135.62 (+3.06)

An Excuse for a Little Profit-Taking
at The Street - Wed Jul 15, 9:25AM CDT
The market needs some consolidation after a four-day run.
SGYP: 8.17 (-0.02), BLUE: 159.39 (-0.10), AMBA: 122.02 (+2.57), NFLX: 107.19 (+0.76), EYES: 14.19 (-0.17), AMZN: 524.40 (-7.01), ZIOP: 12.53 (+0.50), LNKD: 225.82 (+5.16), FB: 94.74 (+0.57), RCPT: 227.75 (+0.66), LBIO: 8.97 (+0.18), INTC: 28.87 (+0.52), ONTY: 3.46 (+0.11), CELG: 135.62 (+3.06)

Strong Finish Is Key for Market
at The Street - Mon Jul 13, 3:18PM CDT
But there's still the problem of limited upside momentum.
BLUE: 159.39 (-0.10), NFLX: 107.19 (+0.76), AMZN: 524.40 (-7.01), TDOC: 30.58 (-0.73), GUID: 9.36 (+0.01), CBM: 46.40 (+0.70), FB: 94.74 (+0.57), LBIO: 8.97 (+0.18), GOOGL: 656.60 (-1.67), MBLY: 58.91 (+0.12), AAPL: 123.32 (+0.55)

Market Action Is Good but the Chase Is Off
at The Street - Mon Jul 13, 11:53AM CDT
There should be a solid close, but it's dead in the meantime.
BLUE: 159.39 (-0.10), NFLX: 107.19 (+0.76), AMZN: 524.40 (-7.01), TDOC: 30.58 (-0.73), GUID: 9.36 (+0.01), CBM: 46.40 (+0.70), FB: 94.74 (+0.57), LBIO: 8.97 (+0.18), GOOGL: 656.60 (-1.67), MBLY: 58.91 (+0.12), AAPL: 123.32 (+0.55)

Stock-Picking Action Looks Good for Bulls
at The Street - Mon Jul 13, 9:17AM CDT
Players are happy to set Greece aside, at least temporarily.
BLUE: 159.39 (-0.10), NFLX: 107.19 (+0.76), AMZN: 524.40 (-7.01), TDOC: 30.58 (-0.73), GUID: 9.36 (+0.01), CBM: 46.40 (+0.70), FB: 94.74 (+0.57), LBIO: 8.97 (+0.18), GOOGL: 656.60 (-1.67), MBLY: 58.91 (+0.12), AAPL: 123.32 (+0.55)

Why Shares in Bluebird Bio Slumped By More Than 10% in June
Todd Campbell, The Motley Fool - Motley Fool - Wed Jul 08, 8:41AM CDT
A narrowing of its collaboration with biotech Goliath Celgene Corp led shares of bluebird bio to tumble 13.3% in June (via data from Capital IQ ). Casting aside CAR-T Bluebird bio and Celgene had previously been collaborating on the...
BLUE: 159.39 (-0.10), CELG: 135.62 (+3.06)

For The Record
at Investor's Business Daily - Mon Jul 06, 5:44PM CDT
For The Record: The ticker symbol of Bluebird Bio (BLUE) is BLUE. The symbol was wrongly identified in an ETFs story that ran July 2 on page A7.
BLUE: 159.39 (-0.10)

Benitec And Bluebird Bio, Gene Therapy Coming Of Age?
Keith Williams - at Seeking Alpha - Mon Jul 06, 11:24AM CDT

BLUE: 159.39 (-0.10), DRNA: 12.89 (+0.19), ALNY: 130.20 (+1.38), TKMR: 10.45 (+0.15), JUNO: 49.02 (+1.22), CELG: 135.62 (+3.06)

Critical Alerts For Seadrill, Health Net Inc., American Airlines, Horizon Pharma and bluebird bio Inc. Released By InvestorsObserver
PR Newswire - Mon Jul 06, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for SDRL, HNT, AAL, HZNP and BLUE.
BLUE: 159.39 (-0.10), HZNP: 38.22 (+2.09), AAL: 41.10 (+0.96), SDRL: 9.03 (+0.75), HNT: 65.82 (+0.22)

Multiple Observations On Celgene's Latest Licensing Deals, And Its Valuation
DoctoRx - at Seeking Alpha - Fri Jul 03, 10:12AM CDT

AGTC: 18.16 (+0.75), BLUE: 159.39 (-0.10), BIIB: 315.64 (+6.21), GILD: 112.96 (+2.42), AZN: 32.87 (+0.16), AMGN: 172.80 (+7.26), JUNO: 49.02 (+1.22), SRNE: 20.40 (-3.30), XLRN: 28.96 (+0.46), CELG: 135.62 (+3.06)

Kite Pharma Gains after Striking KTE-C19 Development Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 02, 4:00PM CDT
Kite Pharma (KITE) inks deal with The Leukemia & Lymphoma Society for the development of KTE-C19 in patients with refractory aggressive non-Hodgkin lymphoma.
BLUE: 159.39 (-0.10), KITE: 72.19 (+3.33), ADMS: 26.83 (+0.68), ACHN: 8.49 (+0.21)

Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point
at The Street - Thu Jul 02, 11:54AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
BLUE: 159.39 (-0.10), GILD: 112.96 (+2.42), MNKD: 4.92 (+0.15), PBYI: 85.69 (+1.00), KERX: 8.12 (+0.46), CELG: 135.62 (+3.06)

Juno-Celgene Deal Has Street Cautiously Optimistic
at Investor's Business Daily - Tue Jun 30, 3:58PM CDT
Shares of biotech startup Juno Therapeutics rose as much as 29% Tuesday, and closed up 15%, as analysts weighed in on its $1 billion deal with Celgene announced late Monday. Celgene (CELG) agreed to pay $150 million upfront and buy 9.1 million Juno...
BLUE: 159.39 (-0.10), KITE: 72.19 (+3.33), CLLS: 36.47 (+1.60), JUNO: 49.02 (+1.22), CYAD: 56.70 (-0.04), CELG: 135.62 (+3.06)

Bit of a Bounce Brings Sigh of Relief
at The Street - Tue Jun 30, 3:12PM CDT
Uncertainty on Greece prevails, but it could have been worse.
SGYP: 8.17 (-0.02), NFLX: 107.19 (+0.76), BLUE: 159.39 (-0.10), AMZN: 524.40 (-7.01), TSLA: 263.78 (+10.77), KITE: 72.19 (+3.33), LBIO: 8.97 (+0.18), JUNO: 49.02 (+1.22), EGRX: 92.95 (+1.72)

A Good Cleanout Is Refreshing
at The Street - Tue Jun 30, 12:57PM CDT
And so is a shift in emotions.
SGYP: 8.17 (-0.02), NFLX: 107.19 (+0.76), BLUE: 159.39 (-0.10), AMZN: 524.40 (-7.01), TSLA: 263.78 (+10.77), KITE: 72.19 (+3.33), LBIO: 8.97 (+0.18), JUNO: 49.02 (+1.22), EGRX: 92.95 (+1.72)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Community Banks Missing $106B Lending Opportunity?

A Missed Opportunity for Community Banks It's a classic tale: community banks sleepwalking while big players snatch up low-hanging fruit right in their own backyards. According to the latest report by Cornerstone Advisors, commissioned by Teslar Software, these banks are essentially leaving $106 billion on the table when it comes to consumer lending. That's not just chump...

ROKFORM’s Signal Card: A Wallet Tracker for All

The Gadget You Didn't Know You Needed Ever feel that momentary panic when your wallet seems to have vanished into thin air? ROKFORM's fresh offering, the Signal Card, tackles that heart-stopping moment head-on. They've taken the mundane act of misplacing your wallet and transformed it with their sleek, credit-card-sized tracker. This baby pairs seamlessly with Apple Find...

Karoo Health Leaps Forward with New CCO Breton

Change of Guard in Cardiac Health at Karoo Here's a move that might shake things up in the healthtech sector: Karoo Health just snagged Angela "Angie" Breton as their new Chief Commercial Officer. It's like putting a seasoned captain at the helm right before setting sail on uncharted waters. Breton's not just any captain—she's got a hefty 25 years of experience...

Navigating Holiday Sweets: Healthy Balancing Acts

In the middle of the sweet madness that is the holiday season, Crispy Green and Dr. Nicole Avena are playing guide to families drowning in sugar. This isn't just a once-a-year Halloween headache; we're starting that sugar spiral early and letting it ride until the New Year approaches. It's an all-hands-on-deck situation if families want to dodge that sugar overload. Why...

Truss Financial Tackles Home Equity Closing Delays

Truss Financial Group's Bold Move Against Closing Delays In real estate, time is money. Even the most casual market observer could tell you delays can slice through a deal like a hot knife through butter. That's the headache home equity borrowers face, blindsided by closing delays that sneak up on them without warning. An Industry Bottleneck Finally Addressed Enter Truss...

Pushing for National Liver Cancer Awareness in 2026

The Urgency of Liver Cancer Awareness Death doesn’t wait, does it? When liver cancer is the villain in question, every moment becomes precious because this beast doesn’t roar until it’s too late. Here we are in 2026, staring at nearly 31,000 annual deaths in the U.S. alone. But hope flickers with a new congressional resolution aiming to slap a bright spotlight on...

TA Services Strengthens U.S.-Mexico Freight Operations

TA Services Moves Boldly Across Borders If ever there was a time to play the logistics chessboard like a champ, it's now, and TA Services just slammed the board with a solid move. They've grabbed Carmen Pacheco Transportation and Interload Forwarding, two family-run operations with some real muscle in North American logistics. This isn't a small-time maneuver; they've...

Northern Jet Names Veteran Matthew Harris as CEO

Fresh Leadership at Northern Jet Well, if you didn’t see this coming, you’ve been snoozing on the tarmac. Northern Jet, no stranger to the skies after three decades, just roped in Matthew Harris as their new CEO from October 2, 2026. They're pulling in this hotshot with more than 25 years riding the turbulence of private aviation. And listen to this: his marching...

JiMMYBAR! Expands Creatine Market with Target Launch

JiMMYBAR! Breaks New Ground in Supplements You ever notice how some companies just know how to shake things up? Take JiMMYBAR!, for instance. The moment I read they’re making moves to get their Creatine + Protein bars into Target stores nationwide, starting October 4, I thought, “That’s one way to drag creatine out from the dusty tub and onto the shelves of...

Cala Launches Game-Changer Wearable for Tremor Relief

Breaking New Ground in Neuromodulation Medical tech's on a roll, and Cala Health just hopped on the fast track with their latest launch—the Cala kIQ Plus System. This bad boy is aiming to offer relief for those grappling with hand tremors, thanks to its FDA clearance and a host of new features. It's the first of its kind, combining multiple therapy modes with an...